M. Parsons
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M. Parsons has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
D. Robinson
Department of Urogynaecology, 3rd Floor, Golden Jubilee Wing, King's College Hospital, London
1 shared publicationL. Cardozo
Department of Urogynaecology, 3rd Floor, Golden Jubilee Wing, King's College Hospital, London
1 shared publication
Latest Publications
- 17 June 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (7) , 831-838
Darifenacin in the treatment of overactive bladder
Antimuscarinic drug therapy has been shown to be effective in the management of patients with symptoms of the overactive bladder syndrome (OAB), but the bothersome antimuscarinic adverse effects of dry mouth, constipation, somnolence and blurred vision often affect compliance with medication. The development of bladder selective M3 specific antagonists offers the possibility of increasing efficacy whilst minimising adverse effects. The M3 specific antagonist solifenacin has recently been marketed, and darifenacin will soon be available. The purpose of this article is to review the pharmacology and clinical trial data available for darifenacin, in addition to examining its role in the treatment of the OBS.
- 17 June 2005
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 59 (7) , 831-838
Darifenacin in the treatment of overactive bladder
Antimuscarinic drug therapy has been shown to be effective in the management of patients with symptoms of the overactive bladder syndrome (OAB), but the bothersome antimuscarinic adverse effects of dry mouth, constipation, somnolence and blurred vision often affect compliance with medication. The development of bladder selective M3 specific antagonists offers the possibility of increasing efficacy whilst minimising adverse effects. The M3 specific antagonist solifenacin has recently been marketed, and darifenacin will soon be available. The purpose of this article is to review the pharmacology and clinical trial data available for darifenacin, in addition to examining its role in the treatment of the OBS.